查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370889

全球地中海贫血治疗市场-产业规模、份额、趋势、机会和预测，2018-2028F 按类型（输血、铁螯合疗法、血液和骨髓移植等）、地区和竞争细分

Global Thalassemia Treatment Market- Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, and Others), By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球地中海贫血治疗市场在2024-2028年预测期内将出现令人印象深刻的成长。这可以归因于地中海贫血及其治疗方案的日益普及。地中海贫血是许多发展中国家，特别是地中海地区的一个主要公共卫生问题。疾病的沉重负担对有效的地中海贫血疫苗产生了强烈需求。这导致了对开发可以预防地中海贫血或减轻其严重程度的疫苗的大量投资。据估计，全球每年约有60,000 至100,000 名婴儿出生时患有严重形式的β-地中海贫血，约占全球人口的1.5%，约80-9000 万是地中海贫血携带者，每年有60,000 人出生时患有地中海贫血。

地中海贫血治疗市场包括输血、铁螯合疗法和骨髓移植等多种疗法。输血是地中海贫血最常见的治疗方法，因为它们有助于用健康的红血球取代有缺陷的红血球。然而，频繁输血会导致体内铁过多，进而导致器官损伤和心臟衰竭等併发症。铁螯合疗法用于去除体内多余的铁，而骨髓移植被认为是地中海贫血的治疗选择。

地中海贫血治疗市场的成长面临多项挑战，包括频繁输血、铁螯合疗法、有限竞争和获得仿製药的机会有限导致的治疗成本以及地中海贫血地区对疫苗犹豫不决和政治不稳定的趋势。开发疫苗需要美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构的批准。这个过程可能漫长且昂贵，而且批准要求可能很严格，使得小公司很难完成这个过程。

市场概况
预测期 2024-2028
2022 年市场规模 18.9亿美元
2028 年市场规模 27.1亿美元
2023-2028 年复合年增长率 6.14%
成长最快的细分市场 输血
最大的市场 北美洲

地中海贫血盛行率增加

地中海贫血盛行率的增加是全球地中海贫血治疗市场的主要驱动力之一。地中海贫血是一种遗传性疾病，最常见于地中海、中东和亚洲血统的人。这些地区地中海贫血的高盛行率导致对有效治疗方案的需求不断增长，并预计全球地中海贫血治疗市场的成长。

医学科学的技术进步预示着市场的成长

医学技术进步在推动全球地中海贫血治疗市场方面发挥了重要作用。新技术和创新技术的发展促进了更有效的地中海贫血治疗方法的开发，改善了患者的治疗结果和生活质量，推动了全球地中海贫血治疗市场的发展。

基因治疗涉及将基因的功能性拷贝插入患者的细胞中以替换有缺陷或缺失的基因。 FDA 批准了地中海贫血基因治疗，每位患者的费用为 280 万美元。这种方法在地中海贫血的治疗中显示出有希望的结果，几种正在开发的基因疗法已显示出显着的疗效，新的基因疗法帮助超过90% 的输血依赖性β地中海贫血成人和儿童患者实现了输血独立。

干细胞移植涉及将健康干细胞移植到地中海贫血患者体内。治疗费用中位数为 12500 美元。这种方法可以为严重地中海贫血患者提供治疗选择，但需要相容的供体，并存在移植相关併发症的风险。从相匹配的非亲缘供体处接受移植的患者的两年无地中海贫血生存率为 71%，而从相匹配的相关供体处接受移植的患者的两年无地中海贫血生存率为 82%。

Cas9是一项革命性的基因编辑技术，能够精确地修饰DNA。该技术有潜力透过纠正潜在的遗传缺陷为地中海贫血患者提供治疗选择，预计将推动全球地中海贫血治疗市场的成长。

未满足的医疗需求增加

未满足的医疗需求的增加是全球地中海贫血治疗市场成长的驱动因素之一。地中海贫血是一种遗传性疾病，会影响血红素的产生，导致贫血和其他併发症。此疾病的严重程度差异很大，患有严重地中海贫血的患者需要定期输血和其他支持性护理来控制症状。一些地中海贫血治疗方法的可用性，例如 Luspatercept 是一种治疗需要定期输血的 B 地中海贫血成人贫血的药物，但在该患者群体中仍然存在显着的未满足的医疗需求。许多患者仍需要频繁输血并遭受与疾病相关的併发症。此外，目前的治疗可能很昂贵，并且需要持续的监测和管理，这可能会给患者及其家人带来负担。对地中海贫血新的、更有效的治疗方法的需求不断增长，特别是那些可以为患者提供治疗选择的方法。这种需求推动了新疗法的开发，例如基因疗法和基因编辑，有可能治癒地中海贫血。新疗法的开发，未满足的医疗需求的增加为现有疗法创造了不断增长的市场，例如输血和螯合疗法。随着地中海贫血的盛行率持续增加，特别是在发展中国家，对这些治疗的需求预计将增长，从而推动全球地中海贫血治疗市场的成长。

市场区隔

全球地中海贫血治疗市场可以按类型和地区细分。根据类型，全球地中海贫血治疗市场可分为输血、铁螯合疗法、血液和骨髓移植等。从地区来看，地中海贫血治疗市场可分为北美、欧洲、亚太地区、南美洲以及中东和非洲。

市场参与者

Bluebird Bio, Inc.、Acceleron Pharma, Inc.、Celgene Corporation、GlaxoSmithKline plc、Incyte Corporation、La Jolla Pharmaceutical Company、Ionis Pharmaceuticals, Inc.、Sanofi SA、Lonza Group Ltd. 和 ApoPharma Inc 是营运中的一些领先参与者在全球地中海贫血治疗市场。

报告范围：

在本报告中，除了以下详细介绍的产业趋势外，全球地中海贫血治疗市场也分为以下几类。

全球地中海贫血治疗市场，按类型：

  • 输血
  • 铁螯合疗法
  • 血液和骨髓移植
  • 其他的

全球地中海贫血治疗市场（按地区）：

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 亚太地区
  • 中国
  • 印度
  • 马来西亚
  • 泰国
  • 越南
  • 南美洲
  • 巴西
  • 阿根廷
  • 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及
  • 巴林
  • 卡达
  • 科威特
  • 土耳其

竞争格局

  • 公司概况：全球地中海贫血治疗市场主要公司的详细分析。

可用的客製化：

  • 根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：COVID-19 对全球地中海贫血治疗市场的影响

第 6 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究类型分類的管道细目
  • 按地区分類的管道明细
  • 临床试验热图

第 7 章：全球地中海贫血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（输血、铁螯合疗法、血液和骨髓移植、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 按类型
    • 按地区

第 8 章：北美地中海贫血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（输血、铁螯合疗法、血液和骨髓移植、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 9 章：欧洲地中海贫血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（输血、铁螯合疗法、血液和骨髓移植、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利

第 10 章：亚太地区地中海贫血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（输血、铁螯合疗法、血液和骨髓移植、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 马来西亚
    • 泰国
    • 越南
    • 印度

第 11 章：南美洲地中海贫血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（输血、铁螯合疗法、血液和骨髓移植、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷

第 12 章：中东和非洲地中海贫血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（输血、铁螯合疗法、血液和骨髓移植、其他）
    • 按国家/地区
  • MEA：国家分析
    • 埃及地中海贫血治疗
    • 南非地中海贫血治疗
    • 沙乌地阿拉伯地中海贫血治疗
    • 阿联酋地中海贫血治疗
    • 巴林地中海贫血治疗
    • 卡达地中海贫血治疗
    • 科威特地中海型贫血治疗
    • 土耳其地中海贫血治疗

第 13 章：市场动态

  • 司机
  • 挑战

第 14 章：市场趋势与发展

  • 产品发布
  • 併购
  • 最近的发展

第 15 章：全球地中海贫血治疗市场：SWOT 分析

第16章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第17章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Bluebird bio, Inc.
    • Acceleron Pharma, Inc.
    • Celgene Corporation
    • GlaxoSmithKline plc
    • Incyte Corporation
    • La Jolla Pharmaceutical Company
    • Ionis Pharmaceuticals, Inc.
    • Sanofi SA
    • Lonza Group Ltd.
    • ApoPharma Inc

第 18 章：策略建议

关于我们及免责声明

简介目录
Product Code: 15590

Global thalassemia treatment market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of thalassemia and its treatment options. Thalassemia is a major public health problem in many developing countries, particularly in Mediterranean region. The high burden of disease has created a strong demand for effective thalassemia vaccines. This has led to significant investment in the development of vaccines that can prevent thalassemia or reduce its severity. It is estimated that there are around 60,000 to 100,000 babies born with severe forms of Beta-thalassemia each year globally, which is around 1.5% of the global population, around 80-90 million are carriers of thalassemia and 60000 individuals are born annually with thalassemia.

The thalassemia treatment market includes various types of therapies such as blood transfusions, iron chelation therapy, and bone marrow transplantation. Blood transfusions are the most common treatment for thalassemia, as they help to replace the defective red blood cells with healthy ones. However, frequent blood transfusions can lead to an excess buildup of iron in the body, which can cause complications such as organ damage and heart failure. Iron chelation therapy is used to remove excess iron from the body, while bone marrow transplantation is considered a curative option for thalassemia.

The growth of the Thalassemia treatment market faces several challenges, including treatment cost due to the frequent blood transfusions, Iron chelation therapy, limited competition, and limited access to generic drugs and the growing trend of vaccine hesitancy and political instability in thalassemic areas. Developing a vaccine requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process can be lengthy and expensive, and the requirements for approval can be stringent, making it difficult for smaller companies to navigate the process.

Market Overview
Forecast Period2024-2028
Market Size 2022USD1.89 Billion
Market Size 2028USD2.71 Billion
CAGR 2023-20286.14%
Fastest Growing SegmentBlood Transfusion
Largest MarketNorth America

Increasing Prevalence of Thalassemia

The increasing prevalence of thalassemia is one of the key drivers of the global thalassemia treatment market. Thalassemia is a genetic disorder that is most found in populations of Mediterranean, Middle East, and Asian descent. The high prevalence of thalassemia in these regions has resulted in growing demand for effective treatment options may be anticipated in the growth of Global thalassemia treatment market.

As the global population continues to grow, the number of people with thalassemia is expected to increase. According to the World Health Organization, thalassemia is one of the most common genetic disorders worldwide, with approximately 300,000 to 500,000 children born with the disease each year. Such increasing prevalence of thalassemia is expected to drive demand for thalassemia treatment market.

Pharmaceutical companies are investing heavily in research and development for new treatments for thalassemia, including gene therapy and fetal hemoglobin induction. These treatments have the potential to provide a curative option for patients with thalassemia, which could significantly improve patient outcomes and quality of life.

Bluebird Bio is developing a gene therapy called Zynteglo (autologous CD34+ cells encoding BA-T87Q-globin gene) for the treatment of transfusion-dependent B-thalassemia. Sangamo Therapeutics is developing a gene therapy called ST-400 for the treatment of B-thalassemia. Hence, it is expected to drive global thalassemia treatment market.

Technological Advancements In Medical Science Promises The Growth Of Market

Technological advancements in medical science have played a significant role in driving the global thalassemia treatment market. The development of new and innovative technologies has enabled the development of more effective treatments for thalassemia, improving patient outcomes and quality of life drives the market of global thalassemia treatment market.

Gene therapy involves the insertion of a functional copy of a gene into a patient's cells to replace a defective or missing gene. FDA approved thalassemia gene therapy treatment costing USD 2.8M per patient. This approach has shown promising results in the treatment of thalassemia, with several gene therapies in development that have shown significant efficacy new gene treatment helped more than 90% of adult and pediatric patients with transfusion-dependent beta-thalassemia achieve transfusion independence.

Stem cell transplantation involves the transplantation of healthy stem cells into a patient with thalassemia. The median cost for treatment is USD 12500. This approach can provide a curative option for patients with severe thalassemia, but it requires a compatible donor and carries the risk of transplant-related complications. Patients who got transplants from matched unrelated donors had a 71% 2-year thalassemia-free survival rate, compared to 82% for patients who received transplants from matched related donors.

Cas9 is a revolutionary gene editing technology that enables precise modification of DNA. This technology has the potential to provide a curative option for patients with thalassemia by correcting the underlying genetic defect is expected to drive the growth of Global Thalassemia Treatment Market.

Increase in Unmet Medical Needs

The increase in unmet medical need has been one of the driving factors behind the growth of the global thalassemia treatment market. Thalassemia is a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications. The severity of the disease can vary widely, and patients with severe forms of thalassemia require regular blood transfusions and other supportive care to manage their symptoms. The availability of some treatments for thalassemia, such as Luspatercept is a treatment for anemia in adults with B-thalassemia who require regular blood transfusions, there remains a significant unmet medical need in this patient population. Many patients still require frequent transfusions and suffer from the complications associated with the disease. In addition, current treatments can be expensive and require ongoing monitoring and management, which can be burdensome for patients and their families. there is a growing demand for new and more effective treatments for thalassemia, particularly those that can provide a curative option for patients. This demand has driven the development of new treatments, such as gene therapy and gene editing, which has the potential to provide a cure for thalassemia the development of new treatments, the increase in unmet medical need has created a growing market for existing treatments, such as blood transfusions and chelation therapy. As the prevalence of thalassemia continues to increase, particularly in developing countries, the demand for these treatments is expected to grow, driving the growth of the global thalassemia treatment market.

Market Segmentation

Global thalassemia treatment market can be segmented by type and region. Based on type, the global thalassemia treatment market can be divided into blood transfusions, iron chelation therapy, blood & bone marrow transplant, and others. Regionally, the thalassemia treatment market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Bluebird bio, Inc., Acceleron Pharma, Inc., Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, La Jolla Pharmaceutical Company, Ionis Pharmaceuticals, Inc., Sanofi S.A., Lonza Group Ltd., and ApoPharma Inc are some of the leading players operating in the global thalassemia treatment market.

Report Scope:

In this report, Global Thalassemia Treatment Market has been segmented into following categories, in addition to the industry trends which have also been detailed below.

Global Thalassemia Treatment Market, By Type:

  • Blood Transfusions
  • Iron Chelation Therapy
  • Blood & Bone Marrow Transplant
  • Others

Global Thalassemia Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia Pacific
  • China
  • India
  • Malaysia
  • Thailand
  • Vietnam
  • South America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Bahrain
  • Qatar
  • Kuwait
  • Turkey

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Thalassemia Treatment Market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Thalassemia Treatment Market

6. Clinical Trial Analysis

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Breakdown of Pipeline, By Development Phase
  • 6.5. Breakdown of Pipeline, By Status
  • 6.6. Breakdown of Pipeline, By Study Type
  • 6.7. Breakdown of Pipeline, By Region
  • 6.8. Clinical Trials Heat Map

7. Global Thalassemia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 7.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 7.2.2. By Region
    • 7.2.3. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Type
    • 7.3.2. By Region

8. North America Thalassemia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 8.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 8.2.2. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Thalassemia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 8.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 8.3.2. Canada Thalassemia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 8.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 8.3.3. Mexico Thalassemia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 8.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

9. Europe Thalassemia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 9.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.2.2. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. Germany Thalassemia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.2. France Thalassemia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.3. United Kingdom Thalassemia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.4. Spain Thalassemia Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.5. Italy Thalassemia Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

10. Asia-Pacific Thalassemia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 10.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.2.2. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Thalassemia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.2. Malaysia Thalassemia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.3. Thailand Thalassemia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.4. Vietnam Thalassemia Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.5. India Thalassemia Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

11. South America Thalassemia Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 11.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 11.2.2. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Thalassemia Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 11.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 11.3.2. Argentina Thalassemia Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 11.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

12. Middle East and Africa Thalassemia Treatment Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 12.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.2.2. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. Egypt Thalassemia Treatment Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.2. South Africa Thalassemia Treatment Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.3. Saudi Arabia Thalassemia Treatment Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.4. UAE Thalassemia Treatment Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.5. Bahrain Thalassemia Treatment Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.6. Qatar Thalassemia Treatment Market Outlook
      • 12.3.6.1. Market Size & Forecast
        • 12.3.6.1.1. By Value
      • 12.3.6.2. Market Share & Forecast
        • 12.3.6.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.6.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.7. Kuwait Thalassemia Treatment Market Outlook
      • 12.3.7.1. Market Size & Forecast
        • 12.3.7.1.1. By Value
      • 12.3.7.2. Market Share & Forecast
        • 12.3.7.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.7.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.8. Turkey Thalassemia Treatment Market Outlook
      • 12.3.8.1. Market Size & Forecast
        • 12.3.8.1.1. By Value
      • 12.3.8.2. Market Share & Forecast
        • 12.3.8.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.8.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Product Launches
  • 14.2. Mergers & Acquisitions
  • 14.3. Recent Developments

15. Global Thalassemia Treatment Market: SWOT Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Company Snapshot
  • 17.3. Products & Services
  • 17.4. Financials (In case of listed companies)
  • 17.5. Recent Developments
  • 17.6. SWOT Analysis
    • 17.6.1. Bluebird bio, Inc.
    • 17.6.2. Acceleron Pharma, Inc.
    • 17.6.3. Celgene Corporation
    • 17.6.4. GlaxoSmithKline plc
    • 17.6.5. Incyte Corporation
    • 17.6.6. La Jolla Pharmaceutical Company
    • 17.6.7. Ionis Pharmaceuticals, Inc.
    • 17.6.8. Sanofi S.A.
    • 17.6.9. Lonza Group Ltd.
    • 17.6.10. ApoPharma Inc

18. Strategic Recommendations

About Us & Disclaimer